Noxopharm Limited, a pharmaceutical company, is focused on developing therapeutic solutions for a range of solid tumor cancers and septic shock, catering to both Australian and international markets. Its primary asset, Veyonda, is currently being developed as an adjuvant therapy, intended to complement chemotherapy and radiotherapy in the treatment of late-stage cancers. The company's robust pipeline includes several programs: The DARRT program, currently in Phase 1b/2a, targets metastatic castration-resistant prostate cancer and other solid tumor types.